CORRALES ALONSO, Sahilí et al. Treatment of chronic hepatitis C with Cuban pegylated interferon and ribavirin. []. , 36, 3, pp. 290-303. ISSN 1684-1824.

Introduction: currently, the association of pegylated interferon and ribavirin is internationally the most accepted therapy for the treatment of chronic hepatitis C. The application of this combination began in Matanzas in 2011, using the Cuban pegylated interferon (PEG-Heberon), setting up a new way in the therapeutic management of this disease. Objective: to describe the first results of the PEG-Heberon and ribavirin application in the treatment of chronic hepatitis C in Matanzas. Methods: descriptive- prospective study. Universe: 19 patients from the provincial consultation of Hepatology of the University Clinic-surgical Hospital Comandante Faustino Pérez in the period from October 2011 to October 2013. The studied variables were: sex, age groups, type of patient, presentation way, adverse reactions, behavior against them, biochemical and virologic answers to treatment. Results: there it was a predominance of female patients (57,9 %); the average age was 41,7 ± 9,2 years; treatment-virgins (73,7 %) and asymptomatic clinical forms (68,4 %). There were adverse reactions in 100 % of the cases; all the clinical ones were mild and among the hematologic ones, 70,4 % were light. There were neither serious events nor cancelations of the treatment. There was a biochemical answer at the end of the treatment in 89,4 % and a maintained one in 78,9 %. The virological answer was achieved at the end of the treatment in 78,9 %, and six months after treatment in 68,4 % of the patients. Conclusion: a high adherence to the combined therapy was achieved, being tolerated and safe for the patient, with acceptable rates of continuous virological answers.

: Cuban pegylated interferon; PEG-Heberon; chronic hepatitis C; virological answers; adverse reactions.

        · |     · |     · ( pdf )